Dr. Michael Alex Papagikos Jr., MD

Dr. Papagikos practices at Coastal Carolina Radiation Oncology in Wilmington, North Carolina.

Dr. Papagikos' NPI, 1831118660, was assigned on July 19, 2006. Dr. Papagikos graduated from Wake Forest School of Medicine in 2001. Dr. Papagikos holds North Carolina license 200401109.

Dr. Papagikos' primary practice is Coastal Carolina Radiation Oncology, at 1988 S 16th St, Wilmington, NC 28401 in New Hanover County. The practice phone is (910) 662-8440.

Dr. Papagikos' primary practice is Coastal Carolina Radiation Oncology in Wilmington, North Carolina. Dr. Papagikos is also affiliated with Novant Health New Hanover Regional Medical Center. The medical group on file is Coastal Carolina Radiation Oncology Center. Dmand AI also links Dr. Papagikos to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Papagikos practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Papagikos' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Papagikos is board certified in radiation oncology by the American Board of Radiology. Dr. Papagikos is licensed in North Carolina.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, lung cancer radiation, lymphoma radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Papagikos treats.

CMS data shows 2,717 Medicare services from Dr. Papagikos across 16 procedure codes in 2024, for 428 Medicare patients. Medicare paid $210,761 for them. Every service was in an office.

CMS counts 428 Medicare patients who saw Dr. Papagikos in 2024. The largest group is 65 to 74, with 228 patients. 75% of them have cancer, and 75% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Papagikos' median patient age at 73, with 20% women.

In 2024, Dr. Papagikos wrote 195 Medicare Part D claims for 85 patients. 99% of them were for generic drugs. CMS names the drug for 173 of them, across 3 drugs with 11 or more claims each, at $1,870 in total drug cost. In 2023, CMS named 182 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Papagikos for performance year 2024, reported as part of a group. Dr. Papagikos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Papagikos as offering telehealth.

Dmand AI links 15 papers to Dr. Papagikos, published from 2013 to 2023. 2013 was the busiest year, with 2. The most frequent topics are Prostatic Neoplasms, Brachytherapy and Radiotherapy Dosage. Dr. Papagikos has published most often in Int J Radiat Oncol Biol Phys. Dr. Papagikos' most frequent co-authors are Christopher H. Crane, MD, Nora Anita Janjan, MD, MPSA, MBA and Anand K. Sharma, MD.

Dmand AI links Dr. Papagikos to 19 clinical trials, 12 of them phase 3 studies. 11 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Intraductal, Noninfiltrating. NRG Oncology sponsors the most, 6.

CMS Open Payments shows 87 general payments to Dr. Papagikos from 24 drug and device companies from 2016 to 2025. Ownership or investment make up the largest share, 88% of the total. Boston Scientific Corporation paid the most, $376,348.

Dmand AI lists 1 award for Dr. Papagikos, most recently CMS Stage 1 EHR in 2013.

Dr. Papagikos graduated from Wake Forest School of Medicine in 2001. Dr. Papagikos is a member of ASCO.

Dr. Papagikos is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.